12.07.2022 - 14.07.2022The Bostonian, 26 North Street, 02109 Boston, Massachusetts, USA
Time: 9:00 AM - 4:30 PM
Kongressthemen There aren’t many targets like BCMA - well validated, preferentially expressed by mature B lymphocytes and specific to multiple myeloma – meaning that novel drugs against BCMA continue to emerge. This brings with it an unmatched therapeutic and commercial opportunity for multiple myeloma patients, a large proportion of whom continue to experience poor tolerability, duration of response and develop resistance.
